RefleXion is a developer of a biology-guided radiotherapy system that aims to create a significant change in strategy from single tumor therapy to the ability to treat multiple tumors in the same treatment session in cancers that have metastasized. The company’s SCINTIX® technology has a mission of tracking period tumor and non-tumor motion to reach its goal of creating a dual treatment modality. RefleXion was founded by Akshay Nanduri and Sam Mazin in 2009 and is headquartered in Hayward, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/15/2023 | Series A-X | $1.92MM | $xx.xx | $1.34B | Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
5,583,233
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock
|
||||||
11/15/2023 | Series B-X | $8.51MM | $xx.xx | $1.34B | Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
7,891,388
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock
|
||||||
11/15/2023 | Series C-X | $16.8MM | $xx.xx | $1.34B | Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
9,928,010
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock
|
||||||
11/15/2023 | Series D-X | $20.47MM | $xx.xx | $1.34B | Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
10,734,817
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock
|
||||||
11/15/2023 | Series D-1-X | $6.55MM | $xx.xx | $1.34B | Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
2,872,489
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock
|
||||||
11/15/2023 | Series E-X | $18.01MM | $xx.xx | $1.34B | Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
7,597,170
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock
|
||||||
11/15/2023 | Series F | $32.74MM | $xx.xx | $1.34B | Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
21,839,817
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge, Catalio, Hillenbrand, Johnson & Johnson Innovation, Pfizer Ventures, Pictet, Square Point Capital, The Rise Fund, T.Rowe Price Associates, Venrock
|
||||||
03/10/2022 | Series E | $110MM | $xx.xx | $785.79MM | Ally Bridge Group, Ascension Ventures, Catalio Capital Management, Hillenbrand Capital Partners, Johnson & Johnson Innovation, Kck Group, Pfizer Ventures Investments, Psp Investments, Sixty Degree Capital, The Rise Fund, T. Rowe Price, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
46,402,813
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge Group, Ascension Ventures, Catalio Capital Management, Hillenbrand Capital Partners, Johnson & Johnson Innovation, Kck Group, Pfizer Ventures Investments, Psp Investments, Sixty Degree Capital, The Rise Fund, T. Rowe Price, Venrock
|
||||||
03/02/2021 | Series D-1 | $40MM | $xx.xx | $650.69MM | Ally Bridge Group | |
Price per Share
$xx.xx
Shares Outstanding
17,544,898
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge Group
|
||||||
04/16/2020 | Series D | $125MM | $xx.xx | $496.89MM | Gt Healthcare Capital Partners, Johnson & Johnson Innovation, Kck Group, Pfizer Venture Investments, Sofinnova Partners, The Rise Fund, T. Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
65,567,269
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Gt Healthcare Capital Partners, Johnson & Johnson Innovation, Kck Group, Pfizer Venture Investments, Sofinnova Partners, The Rise Fund, T. Rowe Price Associates, Venrock
|
||||||
04/04/2018 | Series C | $102.6MM | $xx.xx | $322.47MM | Gt Healthcare Capital Partners, Johnson & Johnson Innovation, Kck Group, Pfizer Venture Investments, Sofinnova Partners, The Rise Fund, T. Rowe Price Associates, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
60,639,366
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Gt Healthcare Capital Partners, Johnson & Johnson Innovation, Kck Group, Pfizer Venture Investments, Sofinnova Partners, The Rise Fund, T. Rowe Price Associates, Venrock
|
||||||
07/19/2016 | Series B | $52MM | $xx.xx | $118.39MM | Johnson & Johnson Innovation, Kck Group, Pfizer Venture Investments, Sofinnova Partners, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
48,199,870
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Johnson & Johnson Innovation, Kck Group, Pfizer Venture Investments, Sofinnova Partners, Venrock
|
||||||
04/04/2014 | Series A | $11.73MM | $xx.xx | $19.55MM | Pfizer Venture, Sofinnova Partners, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
34,101,874
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Pfizer Venture, Sofinnova Partners, Venrock
|